Recent studies have identified potential mechanisms for the development of paclitaxel resistance involving TGFB pathways in ovarian cancer cell lines via [85] and cyclin dependent kinase 14 (CDK14) [86] mediated mechanisms. This evidence concerns the gene CDK14 and ovarian cancer.